Patents by Inventor Jeffrey A. Robl

Jeffrey A. Robl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HMG-CoA reductase inhibitors and method
    Patent number: 7371759
    Abstract: Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis wherein X is N or CR5; and pharmaceutically acceptable salts thereof, wherein R1 to R7 are as defined herein. A method for treating the above diseases employing the above compounds is also provided.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: May 13, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Jeffrey A. Robl, Khehyong Ngu
  • BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION
    Publication number: 20080108649
    Abstract: There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Chong-Qing Sun, Lawrence Hamann, David Augeri, Yingzhi Bi, Jeffrey Robl, Yan-Ting Huang, Tammy Wang, Alexandra Holubec, Ligaya Simpkins, James Sutton, James Li
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Patent number: 7358254
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: April 15, 2008
    Assignees: Bristol-Myers Squibb Company, President & Fellows of Harvard College
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula, Gokhan Hotamisligil
  • Imidazolyl inhibitors of 15-lipoxygenase
    Patent number: 7317032
    Abstract: The present invention provides imidazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: January 8, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David S. Weinstein, Khehyong Ngu, Jeffrey A. Robl
  • NOVEL INHIBITORS OF KINASES
    Publication number: 20070299075
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: August 2, 2007
    Publication date: December 27, 2007
    Inventors: Rajeev Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
  • HMG-CoA reductase inhibitors
    Publication number: 20070249583
    Abstract: Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein A is chosen from B is chosen from wherein the variables R1 to R7, m, n, are as defined herein. A method for treating the above diseases employing the above compounds is also provided.
    Type: Application
    Filed: April 24, 2007
    Publication date: October 25, 2007
    Inventors: Philip D. Stein, Steven P. Seitz, David J. Carini, Yan Shi, Jeffrey A. Robl, Jay A. Markwalder, Chunhong He
  • TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
    Publication number: 20070207985
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.
    Type: Application
    Filed: February 28, 2007
    Publication date: September 6, 2007
    Inventors: Jun Li, Jeffrey Robl, Lawrence Kennedy
  • Inhibitors of kinases
    Patent number: 7265113
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: September 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
  • Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Publication number: 20060287357
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Application
    Filed: June 7, 2006
    Publication date: December 21, 2006
    Inventors: James Li, Lawrence Hamann, Haixia Wang, Zheming Ruan, Christopher Cooper, Jun Li, Jeffrey Robl
  • Heterocyclic aromatic compounds useful as growth hormone secreagogues
    Patent number: 7053110
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably, ?and R1, R1a, R6, Y, Xb, A, B, Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: May 30, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
    Patent number: 6995183
    Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: February 7, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: Lawrence G. Hamann, Ashish Khanna, Mark S. Kirby, David R. Magnin, Ligaya M. Simpkins, James C. Sutton, Jeffrey Robl
  • Bicyclic modulators of androgen receptor function
    Patent number: 6992102
    Abstract: The invention provides compounds of the formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: January 31, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence Hamann, David Augeri, Chongqing Sun, Jeffrey A. Robl, Mark E. Salvati, Tammy Wang
  • Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
    Patent number: 6984645
    Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: David R. Magnin, Richard B. Sulsky, Jeffrey A. Robl, Thomas J. Caulfield, Rex A. Parker
  • Heterocyclic aromatic compounds useful as growth hormone secretagogues
    Patent number: 6969727
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably, and R1, R1a, R6, Y, Xb, A, B, Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: November 29, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li
  • Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
    Publication number: 20050239839
    Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 9, 2005
    Publication date: October 27, 2005
    Inventors: Lawrence Hamann, Ashish Khanna, Mark Kirby, David Magnin, Ligaya Simpkins, James Sutton, Jeffrey Robl
  • Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
    Publication number: 20050228021
    Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 9, 2005
    Publication date: October 13, 2005
    Inventors: Lawrence Hamann, Ashish Khanna, Mark Kirby, David Magnin, Ligaya Simpkins, James Sutton, Jeffrey Robl
  • Heterocyclic containing biphenyl aP2 inhibitors and method
    Patent number: 6927227
    Abstract: aP2 inhibiting compounds are provided having the formula wherein R1, R2, R3, R4, X—Z and are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: August 9, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, David R. Magnin
  • HMG-CoA reductase inhibitors and method
    Publication number: 20050171140
    Abstract: Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.
    Type: Application
    Filed: November 15, 2004
    Publication date: August 4, 2005
    Inventors: Stephen O'Connor, Jeffrey Robl, Saleem Ahmad, Sharon Bisaha, Natesan Murugesan, Khehyong Ngu, Yan Shi, Philip Stein, Nachimuthu Soundararajan, Kenneth Natalie, Laxma Kolla, Justin Sausker, Sandra Quinlan, Junying Fan, Dejah Petsch, Zhenrong Guo
  • Pyridazinone inhibitors of fatty acid binding protein and method
    Patent number: 6919323
    Abstract: aP2 inhibiting compounds are provided having the formula wherein A, X, R and Z are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitors alone or in combination with other therapeutic agents, including other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: July 19, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard Sulsky, Jeffrey A. Robl
  • Heterocyclic aromatic compounds useful as growth hormone secretagogues
    Patent number: 6908938
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and, in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably, and R1, R1a, RY, Xb, A,B,Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: June 21, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, Jun Li